Knight to Present at the 2017 Bloom Burton & Co. Healthcare Investor Conference in Toronto

Knight to Present at the 2017 Bloom Burton & Co. Healthcare Investor Conference in Toronto

ID: 538079

(firmenpresse) - MONTREAL, QUEBEC -- (Marketwired) -- 04/25/17 -- Knight Therapeutics Inc. (TSX: GUD), a leading Canadian specialty pharmaceutical company, announced today that Samira Sakhia, President, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Monday, May 1, 2017 at 11:30am ET at the Sheraton Centre Toronto Hotel. A copy of the presentation will be available at .

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at or .

Forward-Looking Statement

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2016. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.







Contacts:
Knight Therapeutics Inc.
Jeffrey Kadanoff, P.Eng., MBA
Chief Financial Officer
514-484-GUD1 (4831)
514-481-4116 (FAX)

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Acasti Granted Additional Composition & Use Patents in Taiwan and Australia; Safeguards Valuable Market Expansion Opportunities Aevi Genomic Medicine to Present at the 42nd Annual Deutsche Bank Health Care Conference
Bereitgestellt von Benutzer: Marketwired
Datum: 25.04.2017 - 12:00 Uhr
Sprache: Deutsch
News-ID 538079
Anzahl Zeichen: 0

contact information:
Town:

MONTREAL, QUEBEC



Kategorie:

Drugs



Diese Pressemitteilung wurde bisher 240 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Knight to Present at the 2017 Bloom Burton & Co. Healthcare Investor Conference in Toronto"
steht unter der journalistisch-redaktionellen Verantwortung von

Knight Therapeutics Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Knight Reports Third Quarter 2017 Results ...

MONTREAL, QUEBEC -- (Marketwired) -- 11/09/17 -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2017. All dol ...

Knight Announces Changing of the Finance Guard ...

MONTREAL, QUEBEC -- (Marketwired) -- 10/10/17 -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today that Jeffrey Kadanoff, CFO is leaving Knight effective October 13, 2017 ...

Alle Meldungen von Knight Therapeutics Inc.



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z